

DURVALUMAB

Innovatività piena da settembre 2019 a settembre 2022

07/09/2019 – Classe H
Ex-Factory: 2770,09 €
Per giorno di terapia:
296,79 €
Per TTD 166205 €

Mediana 1
infusioni

Mediana 22
infusioni

Mediana di
circa 7 mes

Registro AIF

Mediana 16
infusioni (9
mesi)

Registro AIF

05/11/2022 – Fascia H
Ex-Factory: 2770,9 €
Per giorno di terapia :
296,79 €
Per TTD= 58171.89€

26/07/2018

23/07/2020

△

Effetti collaterali di grado 3 e 4 > 1%: neutropenia, anemia, trombocitopenia, stanchezza, iponatremia, polmoniti, ipertensione, ↑ amilasi e lipasi

Numero mediano di somministrazioni di durvalumab sono 7 (IOR 6–11)

Durata mediana del trattamento di 28 settimane

Studio **CASPIAN**: fase III a 3 bracci: 1) durvalumab + platinum etoposide; 2) durvalumab + tremelimumab + platinum etoposide; 3) platinum etoposide

PFS mediana di 5.1 mes

OS mediana 13 mes

Pazienti naive al trattamento, affetti da ES-SCLC
documentato, PS 0-1; esclusi pz che hanno
ricevuto radioterapia

Non-Small Cell Lung Cancer monoterapia

**Small Cell Lung Cancer con etoposide e/o carboplatino
o cisplatino**

INDICAZIONE

TRIAL REGISTRATIV

FSMO-MCB

FMA

AIF

REAL WORLD EVIDENCE

ONGOING TRIALS

2014

2015

2016

2017

2018

2019

2020

202

202

202

2024

Farmacisti
Ospedali
Ricerca
Indipendente
Economico
Razionale
Ottimo

Referenze

TRIAL REGISTRATIVI

- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. NEJM
- Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol
- Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study. J Thorac Oncol (2023)

REAL WORLD EVIDENCE

- Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer. Cancers
- Durvalumab real-world treatment patterns and outcomes in patients with stage III non-small-cell lung cancer treated in a US community setting (2023)
- Durvalumab Treatment Patterns for Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Veterans Health Administration (VHA): A Nationwide, Real-World Study (2023)